Results 151 to 160 of about 2,551,103 (363)
Hepatic glucocorticoid receptors and the H–2 locus [PDF]
Martin S. Butley+2 more
openalex +1 more source
Objective The aim was to determine patient, disease, and treatment characteristics associated with outcome in patients with primary angiitis of the central nervous system (PACNS) in a large multicenter German cohort. Methods In a retrospective, observational cohort study, we analyzed 163 adult patients who met the diagnostic criteria for PACNS.
Anna Lena Fisse+29 more
wiley +1 more source
Glucocorticoid receptor inactivation under cell-free conditions.
Carl J. Nielsen+3 more
openalex +1 more source
113: Specific 3(H) dexamethasone binding to a thymus cytosol receptor and inhibition of RNAsynthesis by glucocorticoids during postnatal development [PDF]
N. van der Meulen+3 more
openalex +1 more source
Objective Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to ...
Simone Sacco+26 more
wiley +1 more source
Glucocorticoid receptor control of transcription: precision and plasticity via allostery
E. Weikum+3 more
semanticscholar +1 more source
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino+31 more
wiley +1 more source
Specific Cytoplasmic Glucocorticoid Hormone Receptors in Hepatoma Tissue Culture Cells
John D. Baxter, Gordon M. Tomkins
openalex +1 more source
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim+5 more
wiley +1 more source